Sofgen Pharma S.A. (PROCF)
OTCMKTS · Delayed Price · Currency is USD
0.0003
0.00 (0.00%)
Aug 17, 2026, 4:00 PM EST
Sofgen Pharma Revenue
In the year 2024, Sofgen Pharma had annual revenue of $373.80M, down -11.79%. Sofgen Pharma had revenue of $118.41M in the quarter ending September 30, 2023, with 7.25% growth.
Revenue
373.80M
Revenue Growth
-8.48%
P/S Ratio
0.00
Revenue / Employee
83.10K
Employees
4,498
Market Cap
697.44K
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 373.80M | -49.95M | -11.79% |
| Dec 31, 2023 | 423.75M | 20.55M | 5.10% |
| Dec 31, 2022 | 403.20M | -536.00K | -0.13% |
| Jan 1, 2022 | 403.74M | 72.27M | 21.80% |
| Dec 31, 2020 | 331.47M | 6.68M | 2.06% |
| Jan 1, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Tian'an Pharmaceutical | 10.65M |
| Target Group | 3.50M |
| Cannabis Global | 1.06M |
| LiveWire Ergogenics | 571.68K |
| Nutra Pharma | 323.13K |
| Herborium Group | 259.10K |
| Sky Century Investment | 126.22K |
| CBD Life Sciences | 98.32K |
Sofgen Pharma News
- 1 year ago - Procaps Group Secures $130 Million in Equity Investment and Completes Comprehensive Debt Restructuring, as New Investors Take Over Strategic Leadership - GlobeNewsWire
- 1 year ago - Nasdaq delists Colombia's Procaps Group due to financial shortfalls - Invezz